Last reviewed · How we verify
Low Sodium Oxybate
Low sodium oxybate is a reduced-sodium formulation of sodium oxybate that enhances GABAergic and GHB receptor signaling in the central nervous system to reduce excessive daytime sleepiness and cataplexy.
Low sodium oxybate is a reduced-sodium formulation of sodium oxybate that enhances GABAergic and GHB receptor signaling in the central nervous system to reduce excessive daytime sleepiness and cataplexy. Used for Narcolepsy type 1 with cataplexy, Excessive daytime sleepiness in narcolepsy.
At a glance
| Generic name | Low Sodium Oxybate |
|---|---|
| Also known as | XYWAV, JZP-258, Xywav, Calcium, Magnesium, Potassium, and Sodium Oxybates |
| Sponsor | Leiden University Medical Center |
| Drug class | GHB receptor agonist / GABA-B receptor agonist |
| Target | GHB receptor, GABA-B receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Oxybate is a prodrug of gamma-hydroxybutyrate (GHB), which acts as a neuromodulator at GHB receptors and GABA-B receptors in the brain. By lowering sodium content while maintaining therapeutic oxybate levels, this formulation reduces sodium intake burden in patients requiring chronic oxybate therapy, particularly important for those with comorbid hypertension or cardiovascular concerns. The mechanism of action remains identical to standard sodium oxybate, but with improved tolerability regarding sodium-related adverse effects.
Approved indications
- Narcolepsy type 1 with cataplexy
- Excessive daytime sleepiness in narcolepsy
Common side effects
- Nausea
- Dizziness
- Headache
- Enuresis
- Tremor
- Anxiety
Key clinical trials
- Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy (PHASE2)
- Efficacy, Safety and Tolerability of Low Sodium Oxybate for Nocturnal Cluster Headache Attacks (PHASE2)
- Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome (PHASE4)
- A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy (PHASE4)
- Low Sodium Oxybate in Patients With Idiopathic Hypersomnia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |